NEW AWARD FOR DPP-4 SITAGLIPTIN WITH ZYDUS PHARMACEUTICALS (USA)INC. PERIOD OF PERFORMANCE IS 5/18/2024 - 5/17/2025 WITH FOUR ONE-YEAR OPTION PERIODS.

Statistical observations derived from public procurement data. Patterns identified do not constitute findings, accusations, or allegations of wrongdoing. All analysis is based on publicly available records and requires independent verification before any action is taken. This is not legal advice. Terms of Service